PRS3 COST ANALYSIS OF FOURTREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN APPLICATION ON NON-PARAMETRIC BOOTSTRAP  by Fattore, G et al.
A212 Abstracts
PRS2
PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN
SICKNESS FUND POPULATION
Gothe H1, Sandtmann R2, Hoeer A1, Schiffhorst G1, Storz P1,
Glaeske G3, Haeussler B1
1IGES, Berlin, Germany; 2ALTANA Pharma AG, Konstanz, Germany;
3University of Bremen, Bremen, Germany
OBJECTIVES: To investigate into the prescription patterns of
COPD patients. METHODS: Rx claims data were analyzed for
the period from 2001 to 2003. COPD patients were selected
from claims data, if they were at least 45 years of age and had
at least one diagnosis of COPD or emphysema (ICD-10 J43 and
J44) and/or one Rx of a drug for obstructive airway diseases
(ATC code R03) and had no indications of an allergic disease
(e.g., Rx of antihistamines). The percentage of beneﬁciaries with
deﬁned Rx patterns (e.g., combination of bronchodilators) was
analyzed per quarter starting with the quarter of inclusion of
each beneﬁciary. RESULTS: 34,440 COPD patients were
selected, of whom 28,769 received prescriptions of the prede-
ﬁned drug classes. Inhaled corticosteroids (ICS) and short acting
beta agonists were prescribed to most of the beneﬁciaries (42.8
and 40.1%, resp., within three years). Regarding the prescrip-
tion patterns in quarterly periods, ICS and long acting bron-
chodilators were identiﬁed as being the most often prescribed
combination (up to 19% of the beneﬁciaries) followed by long
acting bronchodilators (up to 11% of the beneﬁciaries). Strik-
ingly, the percentage of beneﬁciaries without any Rx of a drug
for obstructive airway diseases was very high. In patients selected
by diagnosis, the percentage of beneﬁciaries without medication
varied between 29 and 57%, whereas for those selected exclu-
sively by drug Rx the percentage ranged from 45 to 71%. CON-
CLUSION: Our ﬁndings demonstrate that the beneﬁciaries
receive prescriptions for long acting bronchodilators and ICS,
either as mono or as combination therapy. In many cases of
COPD, however, there is no long-term drug treatment. Further
research should ﬁnd out whether this means adequate treatment,
regarding the different severity levels of the disease, or indicates
insufﬁcient therapy.
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OBJECTIVES: To evaluate and compare direct health care costs
associated with four alternative treatment strategies used in
patients with moderate-to-severe chronic obstructive pulmonary
disease in Italy. METHODS: Data on resource consumption
were collected alongside 12-month, multinational, randomised,
double-blind, placebo-controlled trail that compared four treat-
ment strategies: budesonide/formoterol combination in a single
inhaler, budesonide as a single therapy, formoterol as a single
therapy and placebo. Economic analysis was conducted on
patients from 6 European countries. The prospective was that of
Italian NHS; national charges and prices were used to evaluate
resource consumption. Average total cost per patient per year
and its conﬁdence intervals was assessed in each group with
bootstrap percentile method. Differences between groups were
tested with bootstrap-Z method. RESULTS: Overall sample
included 272 patients (mean age = 65.3 years) equally distrib-
uted in four treatment groups. The patients treated with budes-
onide/formoterol combination in a single inhaler tended to
consume less health care resources in terms of hospital days and
emergency room visits than patients treated with single drugs.
Average total cost per patient per year was €1763 in group
treated with budesonide/formoterol combination in a single
inhaler, €1436 in budesonide group and €2725 in the formoterol
group. There was no statistically signiﬁcant difference between
the alternative treatment strategies. CONCLUSION: Present
cost analysis suggests that its introduction in the management of
patients with moderate-to-severe chronic obstructive disease
doesn’t increment consumption of health care resources when
compared to single drug alternatives.
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Current practice guidelines for the treatment of COPD recom-
mend the use of combined inhaled corticosteroids and long-
acting bronchodilators in severe and very severe patients (GOLD
stages III and IV). OBJECTIVES: To analyze the economical and
clinical impact of this recommendation, the affordability of its
widespread application, as well as the relative pharmacoeco-
nomic performance of the available options for severe and very
severe COPD in Italy. METHODS: Published data on the Italian
COPD population were ﬁtted in a disease progression model
based on a Markov chain representing severity stages and death.
Alternative therapeutic options (salmeterol/ﬂuticasone—S/F—
formoterol/budesonide—F/B—salmeterol alone—S—ﬂuticasone
alone—F—and control—C) were represented as competing arms
in a decision tree. Efﬁcacy data from international trials were
expressed in terms of risk reduction. Clinical parameters used
were number of exacerbations and symptom-free days. Direct
and indirect costs were considered and valued according to
current prices and tariffs. Analyses were conducted from Italian
National Health Service, societal and patient perspectives with
time horizons of 1, 5, and 10 years and life-long. RESULTS: The
yearly total direct cost of treating COPD patients in Italy is esti-
mated in approximately €7 billion, with a mean cost/patient/year
around €2450. Mean survival of the cohort is 11.5 years. The C
and F strategies are dominated (i.e. are associated with worse
outcomes and higher costs) by all alternatives. S/F and F/B are
the most effective strategies, with a slight clinical superiority 
of S/F, but they are also marginally more expensive than S. 
Incremental cost/effectiveness of S/F vs. S is €679.5/avoided 
exacerbation and 3.3 Euro/ symptom-free day. CONCLUSIONS:
The recommended use of combined inhaled corticosteroids 
and long-acting bronchodilators for severe and very severe
COPD patients, as compared with current practice, has the
potential of improving clinical outcomes without increasing
health care costs.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
has a prevalence of 9.1% in Spain. Exacerbation is one of the
